Name: 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-EU/UK [Time Zone- Central European Time]
Start: 2021-10-26
End: 2021-10-28

CONFERENCE AGENDA

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	14:25 - 14:30
Keynote Presentation: Anti-glycan mabs linked to duocarmycin and PBD payloads as potent drug conjugates Lindy Durrant, Professor of Cancer Immunotherapy, CEO, ScanCell Ltd	14:30 - 15:00
NEXT GEN TARGETED THERAPEUTIC ANTIBODIES AND TUMOR MICROENVIRONMENT
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	15:00 - 15:30
Immunogram & Atlas: An Integrated Multi-Omic Approach and Database to Interrogate the Tumor Microenvironment and Guide CDx Development” Corinne Danan, General Manager, Biopharma, Veracyte	15:30 - 16:00
Customized Recombinant Proteins and Antibodies of Broad-Spectrum to Accelerate Immuno-Oncology Research Linlin Zhang, Technical Specialist, Sino Biological	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Characterizing NSCLC tumor microenvironment using the integrated MultiOmyxTM-RNAscope® workflow Courtney Todorov, Senior Scientist, NeoGenomics	16:45 - 17:15
Two Sides of the same Coin - ImmunoID NeXT and NeXT Liquid Biopsy: Comprehensive Platforms for Tumor Immunogenomics Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc	17:15 - 17:45
Assessing Treatment Benefit in Immuno oncology Laurence Collette, Principal Statistician, Consulting Services, IDDI	17:45 - 18:15
BIG QUESTIONS, SIMPLE SOLUTIONS: Spatial biology in a few and automated steps Barbara Cahill, Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology, , Epredia	18:15 - 18:45
Complete Genomic Profiling for Global Clinical Trials including bTMB Reed Selby, Director of Biopharma Business Development, Predicine	18:45 - 19:15
Modulation of tumor micro-environment by the oncolytic adenovirus ONCOS-102 Victor Levitsky, Chief Scientific Officer, Targovax	19:15 - 19:45
Closing remarks from Chairman	19:45 - 19:50
End of Day 1 and One-one-One Networking	19:50 - 19:55

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman	14:25 - 14:30
Keynote Presentation: Neoantigen Targeted Cancer Immunotherapy in the Clinic Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	14:30 - 15:00
TCR BASED AND CAR-T CELLULAR THERAPY IN IMMUNO-ONCOLOGY
Humanized Mouse Models for Immuno-Oncology Research Kiave-Yune HoWangYin, PhD , Research and Development Director, Transcure Bioservices	15:00 - 15:30
Allogenic Off the Shelf CAR T Cell Therapy Maurizio Chiriva-Internati, Chairman, CEO, Kiromic	15:30 - 16:00
Bioprinted Assembloids: The Next Generation of 3D Tumor Models Priyanka Koti, Bioink Production Engineer, CELLINK	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Next generation CAR T cells engineered for enhanced safety and efficacy in solid tumors Melita Irving, Group Leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Ludwig Institute for Cancer Research	16:45 - 17:15
Humanized mouse model choices for immuno-oncology drug efficacy and toxicity evaluation Juan Liang, Scientist, R&D, GemPharmatech	17:15 - 17:45
Functional phenomics enabling comprehensive analysis of cancer-immune cell interactions at single-cell resolution Robert Weingarten, CSO & Co-Founder, Evorion Biotechnologies	17:45 - 18:15
Next-Generation Humanized Mice Improve Translation of Novel Immunotherapies Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen	18:15 - 18:45
TNFR2 Antagonism and the Tumor Microenvironment Russell LaMontagne, President, CEO, Boston Immune Technologies & Therapeutics	18:45 - 19:15
Nanopore technology - transforming genomics and transcriptomics Miten Jain, Assistant Research Scientist, University of California Santa Cruz	19:15 - 19:45
Closing Remarks from Chairman	19:45 - 19:50
End of Day 2 and One-one-One Networking	19:50 - 19:50

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman	14:25 - 14:30
Keynote Presentation: Precision Medicine Informed Immuno-Oncology is Transforming Cancer Therapy	14:30 - 15:00
ADVANCING PRECISION MEDICINE, BIOMARKERS AND PRECLINICAL DEVELOPMENTS IN IMMUNO-ONCOLOGY
Navigating the Landscape - Curating and Digitizing Public Clinical Trial Data Mark Gramling, PhD, Director, Oncology, Larvol	15:00 - 15:30
T-cell homing in cancer immunotherapy Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University	15:30 - 16:00
Spatial insights into the complexity of the tumor microenvironment Bonnie Phillips, P.hd, Director Field Application Scientist, Ultivue	16:00 - 16:30
Advantages of vaccines over other Immuno-Oncology products John Maudsley, CEO, Cancer Vaccines Ltd	16:30 - 17:00
Discovery and Development of Novel Antibody Fragment Drug Conjugates for Solid Tumours Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	17:00 - 17:30
Therapy of advanced non melanoma skin cancers (NMSC) with ICI: What are the advantages and why? Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	17:30 - 18:00
Advancing immune-oncology drug development with single cell sequencing Ning Wang, Bioinformatics Lead, Arcus Biosciences	18:00 - 18:30
Clinical implementation of SMRT sequencing for Precision Medicine in Immune diseases Paul ‏Keown, Professor of Medicine, University of British Columbia	18:30 - 19:00
Local delivery of anti-PD L1 nanobodies overcomes poor antibody penetration and allows improved blocking of PD-L1 at the tumor site Jingjing Zhu, Senior Research Scientist, Ludwig Institute for Cancer Research	19:00 - 19:30
Closing remarks from Chairman	19:30 - 19:35
End of Day 3 and One-one-One Networking	19:35 - 19:35